Shukra Pharmaceuticals Ltd (BSE: 524632) is a Ahmedabad, Gujarat-based company in the Pharmaceuticals industry. With a market capitalisation of ₹2,839 Cr, it ranks #1,038 by market cap among the 6,189 Indian listed companies on FinBizNet, and #19 of 63 in Pharmaceuticals. At ₹64.58 (as of 26 Oct 2026), the share price is 14.4% below its 52-week high of ₹75.40 and 61.2% above its 52-week low of ₹40.06. The share price is up 97.9% over one year and up 73.2% over three months.
| Current Price | ₹64.58 |
|---|---|
| Market Cap | ₹2,839 Cr |
| BSE Code | 524632 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 129.2 |
| Return on Equity | 28.89% |
| Return on Assets | 18.29% |
| 52-Week Range | ₹40.06 – ₹75.40 |
| 1-Year Price Change | +97.9% |
| 3-Month Price Change | +73.2% |
| Beta (1Y) | 0.38 |
| Dividend Yield | 0.02% |
| Headquarters | Ahmedabad, Gujarat |
| Website | www.shukrapharmaceuticals.com |
| Revenue | ₹24 Cr |
|---|---|
| Net Profit | ₹15 Cr |
| Net Margin | 63.9% |
| EPS (Basic) | ₹0.34 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Shukra Pharmaceuticals Limited manufactures and markets pharmaceutical products in India and internationally. Its product portfolio includes macrolides, quinolones, anti-bacterial, anti-fungal, anti-malarial, anti-viral, anti-protozoal, anti-anthelmintic, sedative and tranquillizer, anti-depressant, anti-manic, anti-emetic, anti-ulcer, beta blockers, diuretics, analgesic, muscle relaxants, anti-tuberculosis, vitamin products, anti-allergics, corticosteroids, hyper and hypoglycemic, and other products, as well as antibiotics, such as penicillin and cephalosporin. The company was formerly known as Relish Pharmaceuticals Limited and changed its name to Shukra Pharmaceuticals Limited in August 2016. Shukra Pharmaceuticals Limited was incorporated in 1993 and is based in Ahmedabad, India.
1. Pharmaceutical-This segment manufactures, exports, and markets various drugs and dosage forms.
1. Pharamaceutical Segment-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹53,132 Cr | 34.2 | 34.46% | ₹1,814 Cr | -16.1% |
| Ajanta Pharma Limited | ₹41,028 Cr | 38.9 | 25.39% | ₹1,626 Cr | +36.3% |
| Emcure Pharmaceuticals Ltd | ₹33,581 Cr | 36.3 | 19.57% | ₹2,580 Cr | +31.1% |
| Piramal Pharma Ltd | ₹25,398 Cr | -77.7 | -4.00% | ₹2,270 Cr | -1.6% |
| RUBICON RESEARCH LIMITED | ₹23,578 Cr | 93 | 19.14% | ₹534 Cr | — |
| Caplin Point Laboratories Ltdte | ₹16,891 Cr | 26.4 | 19.94% | ₹610 Cr | +10.3% |
| Pfizer Ltd. | ₹16,525 Cr | 22.9 | 17.16% | ₹653 Cr | -32.1% |
| Eris Lifesciences Ltd | ₹15,199 Cr | 24.2 | 18.07% | ₹873 Cr | -30.8% |
| Shukra Pharmaceuticals Ltd | ₹2,839 Cr | 129.2 | 28.89% | ₹24 Cr | +97.9% |
Listed by market capitalisation. Ratios are shown for context only.
Shukra Pharmaceuticals Ltd is trading at ₹64.58, with a market capitalisation of ₹2,839 Cr.
Shukra Pharmaceuticals Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Shukra Pharmaceuticals Ltd has a P/E of 129.2 and a return on equity of 28.89%.
Shukra Pharmaceuticals Ltd is listed on the BSE under the scrip code 524632.
Shukra Pharmaceuticals Ltd's share price is up 97.9% over one year and up 73.2% over three months. Its 52-week range is ₹40.06 to ₹75.40.
In Q1 FY27, Shukra Pharmaceuticals Ltd reported revenue of ₹24 Cr and net profit of ₹15 Cr, with basic EPS of ₹0.34 (standalone, parsed from the company's exchange filing).
Data as of 26 Oct 2026. Descriptive market data only — not investment advice.